Cancer gene discovery: Exploiting insertional mutagenesis

Molecular Cancer Research

Volumn 11, Issue 10, 2013, Pages 1141-1158

  Ranzani, Marco ^a   Annunziato, Stefano ^a   Adams, David J ^b   Montini, Eugenio ^a  

^a SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LENTIVIRUS VECTOR; TRANSPOSON;

GENE CASSETTE; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; HEMATOPOIETIC SYSTEM; HUMAN; INSERTIONAL MUTAGENESIS; MAMMARY GLAND; MOLONEY LEUKEMIA ONCOVIRUS; MOUSE MAMMARY TUMOR ONCOVIRUS; MOUSE MODEL; MUTAGENESIS; NONHUMAN; ONCOGENE; PIGGYBAC SYSTEM; PRIORITY JOURNAL; PROMOTER REGION; RETROVIRUS; REVIEW; SLEEPING BEAUTY SYSTEM; TRANSPOSON; TUMOR GENE; TUMOR SUPPRESSOR GENE; ANIMAL; ANTIBODY SPECIFICITY; DISEASE MODEL; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; MOUSE; NEOPLASM; PROCEDURES; PROTO ONCOGENE;

ANIMALS; DISEASE MODELS, ANIMAL; DNA TRANSPOSABLE ELEMENTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; GENES, TUMOR SUPPRESSOR; GENETIC VECTORS; HUMANS; MICE; MUTAGENESIS, INSERTIONAL; NEOPLASMS; ORGAN SPECIFICITY; PROTO-ONCOGENES; RETROVIRIDAE;

EID: 84886411252     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0244     Document Type: Review

References (113)

1. Selten G, Cuypers HT, Zijlstra M, Melief C, Berns A. Involvement of cmyc in MuLV-induced T cell lymphomas in mice: frequency and mechanisms of activation. EMBO J 1984;3:3215-22.
2. Uren AG, Kool J, Berns A, van Lohuizen M. Retroviral insertional mutagenesis: past, present and future. Oncogene 2005;24:7656-72.
3. Morishita K, Parker DS, Mucenski ML, Jenkins NA, Copeland NG, Ihle JN. Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell 1988;54:831-40.
4. van LohuizenM, BreuerM, Berns A. N-myc is frequently activated by proviral insertion in MuLV-induced T cell lymphomas. EMBO J 1989;8:133-6.
5. Kool J, Berns A. High-throughput insertional mutagenesis screens in mice to identify oncogenic networks. Nat Rev Cancer 2009;9:389-99.
6. Selten G, Cuypers HT, Berns A. Proviral activation of the putative oncogene Pim-1 in MuLV induced T-cell lymphomas. EMBO J 1985;4:1793-8.
7. Ceci JD, Patriotis CP, Tsatsanis C, Makris AM, Kovatch R, Swing DA, et al. Tpl-2 is an oncogenic kinase that is activated by carboxyterminal truncation. Genes Dev 1997;11:688-700.
8. Copeland NG, Jenkins NA. Harnessing transposons for cancer gene discovery. Nat Rev Cancer 2010;10:696-706.
9. Coffin JM, Hughes SH, Varmus H. Retroviruses. Plainview, New York: Cold Spring Harbor Laboratory Press; 1997.
10. Fan H. Leukemogenesis by Moloney murine leukemia virus: a multistep process. Trends Microbiol 1997;5:74-82.
11. Starkey CR, Lobelle-Rich PA, Granger SW, Brightman BK, Fan H, Levy LS. Tumorigenic potential of a recombinant retrovirus containing sequences from Moloney murine leukemia virus and feline leukemia virus. J Virol 1998;72:1078-84.
12. Johnson C, Lobelle-Rich PA, Puetter A, Levy LS. Substitution of feline leukemia virus long terminal repeat sequences into murine leukemia virus alters the pattern of insertional activation and identifies new common insertion sites. J Virol 2005;79:57-66.
13. Sorensen KD, Quintanilla-Martinez L, Kunder S, Schmidt J, Pedersen FS. Mutation of all Runx (AML1/core) sites in the enhancer of Tlymphomagenic SL3-3 murine leukemia virus unmasks a significant potential for myeloid leukemia induction and favors enhancer evolution toward induction of other disease patterns. J Virol 2004;78:13216-31.
14. Touw IP, Erkeland SJ. Retroviral insertion mutagenesis in mice as a comparative oncogenomics tool to identify disease genes in human leukemia. Mol Ther 2007;15:13-9.
15. van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H, Berns A. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 1991;65:737-52.
16. Shaughnessy JD, Largaespada DA, Tian E, Fletcher CF, Cho BC, Vyas P, et al. Mrvi1, a common MRV integration site in BXH2 myeloid leukemias, encodes a protein with homology to a lymphoid-restricted membrane protein Jaw1. Oncogene 1999;18:2069-84.
17. Gilbert DJ, Neumann PE, Taylor BA, Jenkins NA, Copeland NG. Susceptibility of AKXD recombinant inbred mouse strains to lymphomas. J Virol 1993;67:2083-90.
18. Li J, Shen H, Himmel KL, Dupuy AJ, Largaespada DA, Nakamura T, et al. Leukaemia disease genes: large-scale cloning and pathway predictions. Nat Genet 1999;23:348-53.
19. Suzuki T, Shen H, Akagi K, Morse HC, Malley JD, Naiman DQ, et al. New genes involved in cancer identified by retroviral tagging. Nat Genet 2002;32:166-74.
20. Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 1982;31:99-109.
21. Hilkens J. Recent translational research: oncogene discovery by insertional mutagenesis gets a new boost. Breast Cancer Res 2006;8:102.
22. Theodorou V, Kimm MA, Boer M, Wessels L, Theelen W, Jonkers J, et al. MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer. Nat Genet 2007;39: 759-69.
23. Klijn C, Koudijs MJ, Kool J, Ten Hoeve J, Boer M, de Moes J, et al. Analysis of tumor heterogeneity and cancer gene networks using deep sequencing of MMTV-induced mouse mammary tumors. PLoS ONE 2013;8:e62113.
24. Koudijs MJ, Klijn C, van der Weyden L, Kool J, ten Hoeve J, Sie D, et al. High-throughput semiquantitative analysis of insertional mutations in heterogeneous tumors. Genome Res 2011;21: 2181-9.
25. Pecenka V, Dvorak M, Karafiat V, Sloncova E, Hlozanek I, Travnicek M, et al. Avian nephroblastomas induced by a retrovirus (MAV-2) lacking oncogene. II. Search for common sites of proviral integration in tumour DNA. Folia Biol (Praha) 1988;34:147-69.
26. Pajer P, Pecenka V, Kralova J, Karafiat V, Prukova D, Zemanova Z, et al. Identification of potential human oncogenes by mapping the common viral integration sites in avian nephroblastoma. Cancer Res 2006;66:78-86.
27. Pajer P, Pecenka V, Karafiat V, Kralova J, Horejsi Z, Dvorak M. The twist gene is a common target of retroviral integration and transcriptional deregulation in experimental nephroblastoma. Oncogene 2003;22:665-73.
28. Uhrbom L, Hesselager G, Nister M, Westermark B. Induction of brain tumors in mice using a recombinant platelet-derived growth factor Bchain retrovirus. Cancer Res 1998;58:5275-9.
29. Johansson FK, Brodd J, Eklof C, Ferletta M, Hesselager G, Tiger CF, et al. Identification of candidate cancer-causing genes in mouse brain tumors by retroviral tagging. Proc Natl Acad Sci U S A 2004;101: 11334-7.
30. Johansson FK, Goransson H, Westermark B. Expression analysis of genes involved in brain tumor progression driven by retroviral insertional mutagenesis in mice. Oncogene 2005;24:3896-905.
31. An W, Han JS, Wheelan SJ, Davis ES,Coombes CE, Ye P, et al. Active retrotransposition by a synthetic L1 element in mice. Proc Natl Acad Sci U S A 2006;103:18662-7.
32. Ostertag EM, DeBerardinis RJ, Goodier JL, Zhang Y, Yang N, Gerton GL, et al. A mouse model of human L1 retrotransposition. Nat Genet 2002;32:655-60.
33. Babushok DV, Ostertag EM, Courtney CE, Choi JM, Kazazian HH. L1 integration in a transgenic mouse model. Genome Res 2006;16: 240-50.
34. Gilbert N, Lutz-Prigge S, Moran JV. Genomic deletions created upon LINE-1 retrotransposition. Cell 2002;110:315-25.
35. Mattison J, van der Weyden L, Hubbard T, Adams DJ. Cancer gene discovery in mouse and man. Biochim Biophys Acta 2009;1796: 140-61.
36. Starr TK, Largaespada DA. Cancer gene discovery using the Sleeping Beauty transposon. Cell Cycle 2005;4:1744-8.
37. Collier LS, Largaespada DA. Hopping around the tumor genome: transposons for cancer gene discovery. Cancer Res 2005;65: 9607-10.
38. Mates L, Chuah MK, Belay E, Jerchow B, Manoj N, Acosta-Sanchez A, et al. Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet 2009;41:753-61.
39. Ivics Z, Hackett PB, Plasterk RH, Izsvak Z. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 1997;91:501-10.
40. Izsvak Z, Ivics Z, Plasterk RH. Sleeping Beauty, a wide host-range transposon vector for genetic transformation in vertebrates. J Mol Biol 2000;302:93-102.
41. Geurts AM, Yang Y, Clark KJ, Liu G, Cui Z, Dupuy AJ, et al. Gene transfer into genomes of human cells by the sleeping beauty transposon system. Mol Ther 2003;8:108-17.
42. Zayed H, Izsvak Z, Walisko O, Ivics Z. Development of hyperactive sleeping beauty transposon vectors by mutational analysis. Mol Ther 2004;9:292-304.
43. Dupuy AJ, Akagi K, Largaespada DA, Copeland NG, Jenkins NA. Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature 2005;436:221-6.
44. Collier LS, Carlson CM, Ravimohan S, Dupuy AJ, Largaespada DA. Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature 2005;436:272-6.
45. Kamijo T, Bodner S, van de Kamp E, Randle DH, Sherr CJ. Tumor spectrum in ARF-deficient mice. Cancer Res 1999;59:2217-22.
46. Dupuy AJ, Rogers LM, Kim J, Nannapaneni K, Starr TK, Liu P, et al. A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice. Cancer Res 2009; 69:8150-6.
47. Starr TK, Allaei R, Silverstein KA, Staggs RA, Sarver AL, Bergemann TL, et al. A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science 2009;323:1747-50.
48. Keng VW, Villanueva A, Chiang DY, Dupuy AJ, Ryan BJ, Matise I, et al. A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol 2009;27:264-74.
49. Starr TK, Scott PM, Marsh BM, Zhao L, Than BL, O'Sullivan MG, et al. A Sleeping Beauty transposon-mediated screen identifies murine susceptibility genes for adenomatous polyposis coli (Apc)-dependent intestinal tumorigenesis. Proc Natl Acad Sci U S A 2011;108: 5765-70.
50. March HN, Rust AG, Wright NA, ten Hoeve J, de Ridder J, Eldridge M, et al. Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis. Nat Genet 2011;43: 1202-9.
51. Berquam-Vrieze KE, Nannapaneni K, Brett BT, Holmfeldt L, Ma J, Zagorodna O, et al. Cell of origin strongly influences genetic selection in a mouse model of T-ALL. Blood 2011;118:4646-56.
52. Karreth FA, Tay Y, Perna D, Ala U, Tan SM, Rust AG, et al. In vivo identification of tumor-suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell 2011;147: 382-95.
53. Vassiliou GS, Cooper JL, Rad R, Li J, Rice S, Uren A, et al. Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice. Nat Genet 2011;43:470-5.
54. van der Weyden L, Giotopoulos G, Rust AG, Matheson LS, van Delft FW, Kong J, et al. Modeling the evolution of ETV6-RUNX1-induced Bcell precursor acute lymphoblastic leukemia in mice. Blood 2011; 118:1041-51.
55. Mann KM, Ward JM, Yew CC, Kovochich A, Dawson DW, Black MA, et al. Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci US A 2012;109:5934-41.
56. Perez-Mancera PA, Rust AG, van der Weyden L, Kristiansen G, Li A, Sarver AL, et al. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 2012;486:266-70.
57. Wu X, Northcott PA, Dubuc A, Dupuy AJ, Shih DJ, Witt H, et al. Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 2012;482:529-33.
58. Koso H, Takeda H, Yew CC, Ward JM, Nariai N, Ueno K, et al. Transposon mutagenesis identifies genes that transform neural stem cells into glioma-initiating cells. Proc Natl Acad Sci U S A 2012;109: E2998-3007.
59. Mumert M, Dubuc A, Wu X, Northcott PA, Chin SS, Pedone CA, et al. Functional genomics identifies drivers of medulloblastoma dissemination. Cancer Res 2012;72:4944-53.
60. Rahrmann EP, Watson AL, Keng VW, Choi K, Moriarity BS, Beckmann DA, et al. Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. Nat Genet 2013;45:756-66.
61. Ding S, Wu X, Li G, Han M, Zhuang Y, Xu T. Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell 2005;122:473-83.
62. Li MA, Pettitt SJ, Eckert S, Ning Z, Rice S, Cadinanos J, et al. The piggyBac transposon displays local and distant reintegration preferences and can cause mutations at noncanonical integration sites. Mol Cell Biol 2013;33:1317-30.
63. Rad R, Rad L, Wang W, Cadinanos J, Vassiliou G, Rice S, et al. PiggyBac transposon mutagenesis: a tool for cancer gene discovery in mice. Science 2010;330:1104-7.
64. Landrette SF, Cornett JC, Ni TK, Bosenberg MW, Xu T. piggyBac transposon somatic mutagenesis with an activated reporter and tracker (PB-SMART) for genetic screens in mice. PLoS ONE 2011; 6:e26650.
65. Cadinanos J, Bradley A. Generation of an inducible and optimized piggyBac transposon system. Nucleic Acids Res 2007;35:e87.
66. Kong J,WangF, Brenton JD, Adams DJ. Slingshot: a PiggyBac based transposon system for tamoxifen-inducible 'self-inactivating, insertional mutagenesis. Nucleic Acids Res 2010;38:e173.
67. Trobridge GD, Russell DW. Helper-free foamy virus vectors. Hum Gene Ther 1998;9:2517-25.
68. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 2000;25:217-22.
69. Vigna E, Naldini L. Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med 2000;2:308-16.
70. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996;272:263-7.
71. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998;72:9873-80.
72. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006;24:687-96.
73. Montini E, Cesana D, Schmidt M, Sanvito F, Bartholomae CC, Ranzani M, et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 2009;119: 964-75.
74. Biffi A, Bartolomae CC, Cesana D, Cartier N, Aubourg P, Ranzani M, et al. Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood 2011;117:5332-9.
75. Scaramuzza S, Biasco L, Ripamonti A, Castiello MC, Loperfido M, Draghici E, et al. Preclinical safety and efficacy of human CD34(β) cells transduced with lentiviral vector for the treatment of Wiskott- Aldrich syndrome. Mol Ther 2013;21:175-84.
76. Galy A, Roncarolo MG, Thrasher AJ. Development of lentiviral gene therapy for Wiskott Aldrich syndrome. Expert Opin Biol Ther 2008; 8:181-90.
77. Naldini L. Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet 2011;12:301-15.
78. Modlich U, Navarro S, Zychlinski D, Maetzig T, Knoess S, Brugman MH, et al. Insertional transformation of hematopoietic cells by selfinactivating lentiviral and gamma retroviral vectors. Mol Ther 2009; 17:1919-28.
79. Schambach A, Zychlinski D, Ehrnstroem B, Baum C. Biosafety features of lentiviral vectors. Hum Gene Ther 2013;24:132-42.
80. Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013 Jul 11. [Epub ahead of print].
81. Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalese MP, Baricordi C, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 2013.
82. Heckl D, Schwarzer A, Haemmerle R, Steinemann D, Rudolph C, Skawran B, et al. Lentiviral vector induced insertional haploinsufficiency of Ebf1 causes murine leukemia. Mol Ther 2012;20:1187-95.
83. Mitchell RS, Beitzel BF, Schroder AR, Shinn P, Chen H, Berry CC, et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol 2004;2:E234.
84. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. Science 2003;300:1749-51.
85. Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002;110:521-9.
86. Cesana D, Sgualdino J, Rudilosso L, Merella S, Naldini L, Montini E. Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations. J Clin Invest 2012;122: 1667-76.
87. Moiani A, Paleari Y, Sartori D, Mezzadra R, Miccio A, Cattoglio C, et al. Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts. J Clin Invest 2012;122: 1653-66.
88. Ranzani M, Cesana D, Bartholomae CC, Sanvito F, Pala M, Benedicenti F, et al. Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer. Nat Methods 2013;10: 155-61.
89. Vigna E, Amendola M, Benedicenti F,Simmons AD, Follenzi A, Naldini L. Efficient Tet-dependent expression of human factor IX in vivo by a new self-regulating lentiviral vector. Mol Ther 2005;11:763-75.
90. Devon RS, Porteous DJ, Brookes AJ. Splinkerettes-improved vectorettes for greater efficiency in PCR walking. Nucleic Acids Res 1995;23:1644-5.
91. Schmidt M, Schwarzwaelder K, Bartholomae C, Zaoui K, Ball C, Pilz I, et al. High-resolution insertion-site analysis by linear amplificationmediated PCR (LAM-PCR). Nat Methods 2007;4:1051-7.
92. Uren AG, Kool J, Matentzoglu K, de Ridder J, Mattison J, van Uitert M, et al. Large-scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes and their collaborative networks. Cell 2008;133:727-41.
93. Uren AG, Mikkers H, Kool J, van der Weyden L, Lund AH, Wilson CH, et al. A high-throughput splinkerette-PCR method for the isolation and sequencing of retroviral insertion sites. Nat Protoc 2009;4: 789-98.
94. Paruzynski A, Arens A, Gabriel R, Bartholomae CC, Scholz S, Wang W, et al. Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing. Nat Protoc 2010;5: 1379-95.
95. Berry CC, Gillet NA, Melamed A, Gormley N, Bangham CR, Bushman FD. Estimating abundances of retroviral insertion sites from DNA fragment length data. Bioinformatics 2012;28:755-62.
96. Brett BT, Berquam-Vrieze KE, Nannapaneni K, Huang J, Scheetz TE, Dupuy AJ. Novel molecular and computational methods improve the accuracy of insertion site analysis in Sleeping Beauty-induced tumors. PLoS ONE 2011;6:e24668.
97. de Ridder J, Uren A, Kool J, Reinders M, Wessels L. Detecting statistically significant common insertion sites in retroviral insertional mutagenesis screens. PLoS Comput Biol 2006;2:e166.
98. Sarver AL, Erdman J, Starr T, Largaespada DA, Silverstein KA. TAPDANCE: an automated tool to identify and annotate transposon insertion CISs and associations between CISs from next generation sequence data. BMC Bioinformatics 2012;13:154.
99. Garraway LA, Lander ES. Lessons from the cancer genome. Cell 2013;153:17-37.
100. Mwenifumbo JC, Marra MA. Cancer genome-sequencing study design. Nat Rev Genet 2013;14:321-32.
101. Bernards R, Brummelkamp TR, Beijersbergen RL. shRNA libraries and their use in cancer genetics. Nat Methods 2006;3:701-6.
102. Mullenders J, Bernards R. Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer. Oncogene 2009;28:4409-20.
103. Liang Q, Kong J, Stalker J, Bradley A. Chromosomal mobilization and reintegration of Sleeping Beauty and PiggyBac transposons. Genesis 2009;47:404-8.
104. Faschinger A, Rouault F, Sollner J, Lukas A, Salmons B, Gunzburg WH, et al. Mouse mammary tumor virus integration site selection in human and mouse genomes. J Virol 2008;82:1360-7.
105. Sauvageau M, Miller M, Lemieux S, Lessard J, Hebert J, Sauvageau G. Quantitative expression profiling guided by common retroviral insertion sites reveals novel and cell type specific cancer genes in leukemia. Blood 2008;111:790-9.
106. Suzuki T, Minehata K, Akagi K, Jenkins NA, Copeland NG. Tumor suppressor gene identification using retroviral insertional mutagenesis in Blm-deficient mice. EMBO J 2006;25:3422-31.
107. Suerth JD, Maetzig T, Brugman MH, Heinz N, Appelt JU, Kaufmann KB, et al. Alpharetroviral self-inactivating vectors: long-term transgene expression in murine hematopoietic cells and low genotoxicity. Mol Ther 2012;20:1022-32.
108. Suerth JD, Maetzig T, Galla M, Baum C, Schambach A. Self-inactivating alpharetroviral vectors with a split-packaging design. J Virol 2010;84:6626-35.
109. Lee E, Iskow R, Yang L, Gokcumen O, Haseley P, Luquette LJ III, et al. Landscape of somatic retrotransposition in human cancers. Science 2012;337:967-71.
110. Shukla R, Upton KR, Munoz-Lopez M, Gerhardt DJ, Fisher ME, Nguyen T, et al. Endogenous retrotransposition activates oncogenic pathways in hepatocellular carcinoma. Cell 2013;153: 101-11.
111. Solyom S, Ewing AD, Rahrmann EP, Doucet T, Nelson HH, Burns MB, et al. Extensive somatic L1 retrotransposition in colorectal tumors. Genome Res 2012;22:2328-38.
112. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, et al. Insertional oncogenesis in 4 patients after retrovirus- mediated gene therapy of SCID-X1. J Clin Invest 2008;118: 3132-42.
113. Baum C, Schambach A, Bohne J, Galla M. Retrovirus vectors: toward the plentivirus? Mol Ther 2006;13:1050-63.